LONDON, UK / ACCESSWIRE / October 10, 2022 / ReNeuron Group, a stem cell-derived exosome technology company, has presented encouraging preclinical data highlighting the enhanced drug delivery capability of its customisable exosome platform (CustomEx) over conventional human embryonic kidney-derived (HEK) exosomes. The company's CustomEx exosomes displayed a minimum 10-fold increase in cellular uptake across three cell types (endothelial, neural and epithelial) compared to HEK-derived exosomes, with an 18-fold increase observed in endothelial cells. Additionally, when loaded with a therapeutic payload (small interfering RNA, siRNA), a 600% improvement in delivery to the target cell was recorded versus HEK exosomes. The most advanced exosome technologies that have entered clinical development, to date, are HEK-derived exosomes. We believe these results therefore not only provide encouraging signs for the clinical progression of ReNeuron's exosomes, but may also provide a distinct competitive advantage against HEK competitors. Our estimates are currently under review.
Notably, the study was able to demonstrate the effective delivery of siRNA, a new class of complex drug modality, in which targeted drug delivery remains a significant challenge. The RNA therapeutic pipeline is poised to deliver further drug candidates, so we view this market as a potential opportunity for ReNeuron to target. While therapeutic exosomes may still be in the early stages of clinical development, demonstrating positive preclinical data has led to the signing of significant licensing deals within the market. This latest data will therefore further promote ReNeuron's technology platform and may garner heightened interest from potential partners, in our view.
Click here to view the full report or here to sign up to receive research as it is published.
All reports published by Edison are available to download free of charge from its website www.edisongroup.com
About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.
Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information, please contact Edison:
Soo Romanoff +44 (0)20 3077 5700 [email protected]
Learn more at www.edisongroup.com and connect with Edison on:
LinkedIn www.linkedin.com/company/edison-group-/
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv
SOURCE: Edison Investment Research Limited